A high-stakes competition is unfolding among major pharmaceutical players, including Novartis, Amgen, and Eli Lilly, as they race to develop a groundbreaking class of heart medication. The focus of this research is lipoprotein(a), or Lp(a), a form of cholesterol determined by genetics that significantly elevates the risk of stroke and heart attack. Unlike standard LDL […]